US Patent
US7977488 — 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Composition of Matter · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2030-04-10 · 4y remaining
Vulnerability score
18/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects a class of compounds, specifically 1-H-pyrrole derivatives, that inhibit acid secretion and have antiulcer activity.
USPTO Abstract
The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R 1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R 2 is an optionally substituted C 6-14 aryl group, an optionally substituted thienyl group or an optionally substituted pyridyl group, R 3 and R 4 are each a hydrogen atom, or one of R 3 and R 4 is a hydrogen atom and the other is an optionally substituted lower alkyl group, an acyl group, a halogen atom, a cyano group or a nitro group, and R 5 is an alkyl group or a salt thereof.
Drugs covered by this patent
- Amoxil (amoxicillin) · Generic (originally Beecham/GSK)
- vonoprazan-fumarate (VONOPRAZAN FUMARATE)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.